mRNA-Vaccines: Breakthrough or Blunder? What We Know — and What We Don’t
Laura Chrobok 07.11.2025
A technology hailed as a milestone, yet viewed with growing caution: mRNA vaccines. Since the COVID-19 pandemic, they’ve been praised as a medical innovation—but also met with public skepticism.
Read about the basics of mRNA technology, learn what is considered established knowledge, and which questions remain unanswered!
Follow the Money
Let’s be clear from the start: yes, it’s also about money. During Germany’s COVID-19 vaccination campaign, physicians received special payments for every shot they administered—a point still debated today.
According to the National Association of Statutory Health Insurance Physicians (KBV), the initial fee was €20 per vaccination, later raised to €28, and up to €36 on weekends and public holidays (KBV, 2021/22).
This applied to all approved vaccines, including the mRNA shots from BioNTech/Pfizer and Moderna, which accounted for most vaccinations. Payments came from federal funds via regional physician associations. Similar rules applied to pharmacies and mobile centers under medical supervision.
Officially, the higher pay was to compensate for extra administrative work—documentation, patient counseling, and digital data entry. Yet skeptics viewed it as a financial incentive potentially fueling vaccination enthusiasm. Unlike routine vaccinations, this was an exceptional fee outside normal reimbursement systems.
Medical chambers argued the administrative burden was immense and justified the supplement (Ärztezeitung, 24.03.2023).
The fees were reduced in 2023 as the campaign wound down, transitioning into regular care.
Reports suggested even higher real payments in vaccination centers — including hourly flat rates for doctors, sometimes reaching several hundred euros (Capital, 26.12.2021).
The government’s aim was rapid mass vaccination while ensuring doctors didn’t neglect other services. Yet whenever financial incentives meet political pressure, conflicts of interest follow.
Data Collection as a Pretext for “Vaccination Quotas” from 2026?!
Online debates increasingly focus on alleged “vaccination quotas” doctors must meet from 2026 onward. Officials deny any legal obligation.
However, a closer look at recent legislation suggests the infrastructure for such monitoring already exists.
Through the ongoing digitalization of healthcare, treatment data will soon be centrally collected and analyzed—including how many vaccinations each practice performs. This framework is established in Germany’s Digital Healthcare Act (DVG) and the new Health Data Utilization Act (GDNG) (Federal Ministry of Health, 2019, 2024).
The Institute for Quality Assurance and Transparency in Healthcare (IQTIG) is already developing “quality indicators” that include vaccination statistics (IQTIG, 2024).
Officially, these metrics are meant for “quality assurance.” Yet when reimbursement models or contracts begin to rely on these indicators, financial pressure on physicians could follow. Even the KBV acknowledges that preventive indicators might become relevant for future compensation (KBV, 2024).
In other words: no law currently forces doctors to vaccinate more—but the structures for such control are already in place. And history shows how voluntary data collection can easily turn into mandatory oversight.
Who Profits Financially?
When health and digital policy intertwine, new markets emerge—not necessarily to the benefit of patients.
Legislation like the Digital Healthcare Act (DVG) created reimbursement options for digital medical products (“apps on prescription”), opening lucrative opportunities for health-tech developers and IT service providers.
Insurers also benefit indirectly: bonus programs already reward policyholders for preventive actions, including vaccinations. The more vaccinations are billed, the greater the potential for such programs.
Meanwhile, as data collection expands under the GDNG, the value of health data grows—attracting research institutions, data analytics firms, and digital platforms.
But How Do mRNA Vaccines Actually Work?
mRNA stands for “messenger ribonucleic acid”.
It’s a natural molecule in every cell, acting as a messenger between DNA and the cell’s protein factories (ribosomes). When the cell needs to make a protein, it copies a gene segment from DNA into an mRNA molecule, which carries the instructions to produce that protein.
mRNA vaccines mimic this process. They deliver synthetic mRNA encoding a viral protein—usually the SARS-CoV-2 spike protein. Cells make this protein, prompting the immune system to recognize it as foreign and create antibodies and specific immune cells. Unlike traditional vaccines, these are molecular platforms, not live or inactivated virus preparations (Pardi et al., 2018).
The mRNA is encased in lipid nanoparticles (LNPs) that protect it and help it enter cells. These lipid carriers are essential for efficacy but may also trigger inflammatory reactions—useful for immune activation, yet potentially problematic for sensitive individuals.
Studies show that LNPs can themselves stimulate immune responses, raising questions about long-term safety (Hou et al., 2021).
Ongoing research explores mRNA technology for:
· cancer treatment
· viral diseases (e.g., HIV)
· autoimmune and metabolic disorders (e.g., diabetes)
· cardiovascular conditions
Once the body has produced the target protein, the mRNA degrades. But that’s where the unanswered questions begin.
What Is unclear
Unresolved issues include:
· How long does immunity really last?
· How do lipid nanoparticles affect different organs?
· How stable is mRNA in human tissues?
· Does it reach organs like the liver, spleen, or lymph nodes?
· Can it trigger inflammation in unintended areas?
· Are autoimmune reactions possible over time?
· What are the long-term effects of repeated exposure?
Long-term studies, such as the Danish ENFORCE cohort (Stærke et al., 2022), emphasize the need for multi-year observation to detect potential adverse effects.
Without comprehensive longitudinal data—which, so far, do not exist—we simply don’t know what these technologies might mean for human health.
Risks and Side Effects
Aches, fatigue, fever … too bad the side effects mimic the very symptoms they’re meant to prevent.
Confirmed complications include myocarditis and pericarditis, especially among young men after the second dose (Oster et al., 2022).
Other observed effects:
· temporary changes in menstrual cycles (Edelman et al., 2022)
· allergic or immune reactions (Shimabukuro et al., 2021)
Conclusion: A Backdoor Push for Mandatory Vaccinations … and Many Unknowns
Without unbiased long-term observation, mRNA vaccines amount to not much else than a money-printing machine and a grand experiment with an open outcome—one that also seems to aim at creating the transparent citizen.
But who wants to be that … and a lab rat on top of it?
So, in the end, just backroom deals and unanswered questions?
Not entirely ...
FAQ – Frequently Asked Questions About mRNA-Vaccines
1. Can mRNA vaccines affect other biological processes in the body?
Immunologists suggest they may alter cytokine or hormone activity, similar to natural infection responses. Studies are examining whether repeated doses influence stress hormones or inflammatory markers.
2. How does mRNA behave in bodies with weak or overactive immune systems?
In immunocompromised individuals, uptake and processing may be reduced, yielding weaker protection. Conversely, overly active immune systems could overreact—data remain limited.
3. What do we know about long-term spike protein exposure?
Animal and case studies hint that traces may persist longer than expected. Whether these have biological consequences is unknown—independent long-term studies are lacking!
4. How will repeated mRNA exposure affect immunity over decades?
No one can yet answer that. Experts call for decades-long cohort studies before mRNA vaccines can be deemed “safe over time.”
Further information on vaccinations and other topics can be found in the individual posts on our blog. You can also visit our online shop, where you’ll find volumes of our “Codex Humanus” and the “Medizinskandale” series.
Sources:
- Kassenärztliche Bundesvereinigung (2021/22): “COVID-19-Impfung (Vergütung, Vorgehen, Abrechnung)”
Online: https://www.kbv.de/html/covid-19-impfung.php
- Ärztezeitung (24.03.2023): “KVen und Kassen noch weit entfernt von Einigung zum Honorar für COVID-Impfung”
- Capital (26.12.2021): “Das verdienen Ärzte, die gegen Corona impfen”
Online: https://www.capital.de/allgemein/das-verdienen-aerzte-die-gegen-corona-impfen
- Bundesministerium für Gesundheit (2019): Gesetz für eine bessere Versorgung durch Digitalisierung und Innovation – Digitales-Versorgung-Gesetz (DVG).
- Bundesministerium für Gesundheit (2024): Gesetz zur Nutzung von Gesundheitsdaten im Gesundheits- und Pflegebereich – Gesundheitsdatennutzungsgesetz (GDNG).
- Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG) (2024): Bundesqualitätsbericht 2024 – Verfahrensübergreifender Teil.
- Kassenärztliche Bundesvereinigung (KBV): Qualitätsbericht 2024 – Vertragsärztliche Versorgung.
- Pardi, N. et al. (2018): “mRNA vaccines — a new era in vaccinology,” Nature Reviews Drug Discovery.
- Hou, X. et al. (2021): “Lipid nanoparticles for mRNA delivery,” Nature Reviews Materials.
- Stærke, N.B. et al. (2022): “Cohort Profile: The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE),” BMJ Open.
- Oster, M.E. et al. (2022): “Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US,” JAMA.
- Edelman, A. et al. (2022): “Association between menstrual cycle length and COVID-19 vaccination: a U.S. cohort,” BMJ..
- Shimabukuro, T.T. et al. (2021): “Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine,” JAMA.